NPs Basic Information
|
Name |
Oxacyclotetradec-3-en-2-one, 5,6,8-trihydroxy-14-pentyl-, (3E)-
|
| Molecular Formula | C18H32O5 | |
| IUPAC Name* |
(3Z)-5,6,8-trihydroxy-14-pentyl-1-oxacyclotetradec-3-en-2-one
|
|
| SMILES |
CCCCCC1CCCCCC(CC(C(/C=C\C(=O)O1)O)O)O
|
|
| InChI |
InChI=1S/C18H32O5/c1-2-3-5-9-15-10-7-4-6-8-14(19)13-17(21)16(20)11-12-18(22)23-15/h11-12,14-17,19-21H,2-10,13H2,1H3/b12-11-
|
|
| InChIKey |
LEEBEEPDVOWSDN-QXMHVHEDSA-N
|
|
| Synonyms |
Oxacyclotetradec-3-en-2-one, 5,6,8-trihydroxy-14-pentyl-, (3E)-; Sch-725674; 877061-66-0
|
|
| CAS | NA | |
| PubChem CID | 101768830 | |
| ChEMBL ID | NA |
*Note: the IUPAC Name was collected from PubChem.
Chemical Classification: |
|
|
|---|
——————————————————————————————————————————
NPs Species Source
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
|---|---|---|---|---|---|---|---|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
NPs Biological Activity
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
NPs Physi-Chem Properties
| Molecular Weight: | 328.4 | ALogp: | 3.1 |
| HBD: | 3 | HBA: | 5 |
| Rotatable Bonds: | 4 | Lipinski's rule of five: | Accepted |
| Polar Surface Area: | 87.0 | Aromatic Rings: | 1 |
| Heavy Atoms: | 23 | QED Weighted: | 0.545 |
——————————————————————————————————————————
NPs ADMET Properties*
ADMET: Absorption
| Caco-2 Permeability: | -4.829 | MDCK Permeability: | 0.00003540 |
| Pgp-inhibitor: | 0.956 | Pgp-substrate: | 0.98 |
| Human Intestinal Absorption (HIA): | 0.213 | 20% Bioavailability (F20%): | 0.995 |
| 30% Bioavailability (F30%): | 0.634 |
——————————————————————————————————————————
ADMET: Distribution
| Blood-Brain-Barrier Penetration (BBB): | 0.488 | Plasma Protein Binding (PPB): | 57.78% |
| Volume Distribution (VD): | 1.42 | Fu: | 28.11% |
——————————————————————————————————————————
ADMET: Metabolism
| CYP1A2-inhibitor: | 0.011 | CYP1A2-substrate: | 0.299 |
| CYP2C19-inhibitor: | 0.025 | CYP2C19-substrate: | 0.338 |
| CYP2C9-inhibitor: | 0.051 | CYP2C9-substrate: | 0.642 |
| CYP2D6-inhibitor: | 0.002 | CYP2D6-substrate: | 0.095 |
| CYP3A4-inhibitor: | 0.029 | CYP3A4-substrate: | 0.102 |
——————————————————————————————————————————
ADMET: Excretion
| Clearance (CL): | 10.179 | Half-life (T1/2): | 0.927 |
——————————————————————————————————————————
ADMET: Toxicity
| hERG Blockers: | 0.042 | Human Hepatotoxicity (H-HT): | 0.171 |
| Drug-inuced Liver Injury (DILI): | 0.285 | AMES Toxicity: | 0.534 |
| Rat Oral Acute Toxicity: | 0.182 | Maximum Recommended Daily Dose: | 0.807 |
| Skin Sensitization: | 0.773 | Carcinogencity: | 0.035 |
| Eye Corrosion: | 0.045 | Eye Irritation: | 0.451 |
| Respiratory Toxicity: | 0.412 |
——————————————————————————————————————————
*Note: the ADMET properties was calculated by ADMETlab 2.0. Reference: PMID: 33893803.
Similar Compounds*
Compounds similar to EMNPD with top10 similarity:
| Similar NPs | Similar Drugs | ||||||
|---|---|---|---|---|---|---|---|
| NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
| ENC006036 |  |
1.000 | D0XN8C |  |
0.255 | ||
| ENC004295 |  |
0.781 | D01WUA |  |
0.254 | ||
| ENC002200 |  |
0.521 | D0HR8Z |  |
0.253 | ||
| ENC002098 |  |
0.521 | D0V0IX |  |
0.252 | ||
| ENC003404 |  |
0.462 | D07GRH |  |
0.247 | ||
| ENC004377 |  |
0.462 | D04URO |  |
0.238 | ||
| ENC005833 |  |
0.432 | D0I4DQ |  |
0.231 | ||
| ENC005864 |  |
0.421 | D06WTZ |  |
0.231 | ||
| ENC003241 |  |
0.385 | D0Y7IU |  |
0.230 | ||
| ENC004121 |  |
0.384 | D04QNO |  |
0.230 | ||